Celecoxib/sorafenib: Capillary leak syndrome.

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 29-year-old woman developed capillary leak syndrome during treatment with sorafenib and celecoxib for desmoid tumour of the thigh. [Extracted from the article]